Department of Gastroenterology, Charité Campus Benjamin Franklin, Berlin, Germany.
Eur J Cancer Prev. 2012 Sep;21(5):413-22. doi: 10.1097/CEJ.0b013e32834ef16f.
Ursodeoxycholic acid (UDCA) can prevent chemical and colitis-associated colon carcinogenesis by unknown mechanism(s). One of the processes underlying the chemopreventive action could be the inhibition of proliferation by UDCA. To clarify the antiproliferative mechanism of UDCA, we used p53 wt colon carcinoma cell lines HCT8 and HCT116. UDCA-induced inhibition of proliferation was reversible and was associated with a decrease of the S-phase and an increase of G1 phase population, but not with apoptosis or senescence. The treatment suppressed the expression of c-Myc protein and, as a consequence, of several cell cycle regulatory molecules, including CDK4 and CDK6. Using the HCT8 cell line as a model, we show that UDCA suppresses c-Myc at the protein level. The suppression of c-Myc alone or a simultaneous suppression of CDK4 and of CDK6 kinase is sufficient to inhibit cell proliferation. In sum, we identified c-Myc as a primary UDCA target in colon carcinoma cells. The degradation of c-Myc protein decreases the expression of the cell cycle regulators CDK4 and CDK6, which reversibly slows down the cell cycle. The suppression of these proproliferatory molecules is the likely initial mechanism of antiproliferatory action of UDCA on colon cancer cells.
熊去氧胆酸(UDCA)通过未知机制预防化学物质和结肠炎相关的结肠癌发生。化学预防作用的过程之一可能是 UDCA 抑制增殖。为了阐明 UDCA 的抗增殖机制,我们使用 p53 wt 结肠癌细胞系 HCT8 和 HCT116。UDCA 诱导的增殖抑制是可逆的,并与 S 期减少和 G1 期增加相关,但与细胞凋亡或衰老无关。该治疗抑制了 c-Myc 蛋白的表达,从而抑制了几个细胞周期调节分子,包括 CDK4 和 CDK6。我们使用 HCT8 细胞系作为模型,表明 UDCA 在蛋白水平上抑制 c-Myc。单独抑制 c-Myc 或同时抑制 CDK4 和 CDK6 激酶足以抑制细胞增殖。总之,我们确定 c-Myc 是结肠癌细胞中 UDCA 的主要靶标。c-Myc 蛋白的降解降低了细胞周期调节剂 CDK4 和 CDK6 的表达,从而使细胞周期可逆性减慢。抑制这些促增殖分子可能是 UDCA 对结肠癌细胞的抗增殖作用的初始机制。